Atrys Business Model Canvas
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Atrys Bundle
Unlock Healthcare Diagnostics Business Model Canvas — Ready-to-Use Strategic Blueprint
Unlock Atrys’s full Business Model Canvas to see exactly how the company creates value, scales services, and captures healthcare and diagnostics market share. This concise, actionable canvas breaks down customer segments, revenue streams, partnerships and cost structure—ready in Word and Excel. Purchase the complete file for a practical, ready-to-use strategic blueprint ideal for investors, consultants, and founders.
Partnerships
Hospitals and clinics
Partner with public and private hospitals to integrate diagnostics, imaging and oncology workflows, leveraging Atrys networks expanded in 2024 to deepen clinical ties across Spain and Latin America.
Co-develop care pathways and referral protocols to streamline patient intake and reduce delays between diagnosis and treatment.
Enable integrated data exchange with shared quality metrics and support multi-site coverage to ensure continuity of care across hospital networks.
Academic and research institutions
Collaborate with academic and research institutions on clinical trials, genomics research, and validation studies to access novel biomarkers, advanced imaging protocols, and robust evidence generation. Co-author peer-reviewed publications to strengthen clinical credibility and market acceptance. Leverage 2024 research funding streams such as Horizon Europe and institutional grants to subsidize trials and use shared research infrastructure for scale.
Technology and AI vendors
Form alliances with AI, cloud and cybersecurity providers to scale Atrys platforms, tapping a healthcare AI market that surpassed $20B in 2024 and a global cloud services market above $600B. Integrate best-in-class imaging, pathology and genomics algorithms to raise diagnostic accuracy and throughput. Ensure interoperable, regulatory-grade data pipelines to accelerate product roadmaps and cut time-to-market.
Medical device and pharma companies
Atrys partners with medical device and pharma firms to provide companion diagnostics, theranostics, and treatment-planning tools, supporting biomarker-driven patient selection for trials and commercialization; global companion diagnostics market ~6.3 billion USD in 2024. Co-creation of post-market evidence and RWD programs strengthens regulatory positioning and safety signals while joint commercialization expands distribution and revenue reach.
- Companion diagnostics: co-development
- Biomarker-based patient selection: trial enrichment
- RWD/post-market: evidence generation
- Joint commercialization: channel expansion
Payers and health systems
Atrys partners with payers and health systems to align on value-based care and reimbursement pathways, pilot bundled payments for diagnostics and oncology episodes, and share risk through outcome-based contracts tied to clinical benchmarks while integrating services into payer networks and formularies to improve access.
- Value-based alignment
- Bundled diagnostics/onco pilots
- Outcome-based risk sharing
- Payer network integration
Integrate diagnostics, imaging and oncology across Spain & LATAM in 2024
Partner with public/private hospitals to integrate diagnostics, imaging and oncology workflows, leveraging Atrys network expansion in 2024 across Spain and Latin America.
Co-develop care pathways, referral protocols and shared data exchange to shorten diagnosis-to-treatment times and ensure multi-site continuity.
Alliances with AI/cloud/cybersecurity vendors and pharma/device firms accelerate regulatory-grade algorithms and companion diagnostics; healthcare AI market ~$20B (2024), cloud ~$600B (2024), companion dx ~$6.3B (2024).
| Partner | 2024 metric |
|---|---|
| AI market | $20B |
| Cloud market | $600B |
| Companion dx | $6.3B |
What is included in the product
Detailed Word Document
A comprehensive, pre-written Business Model Canvas for Atrys covering all nine BMC blocks—customer segments, value propositions, channels, revenue streams, key partners, activities, resources and cost structure—with practical insights, competitive advantages and linked SWOT for investor-ready presentations and strategic decisions.
Customizable Excel Spreadsheet
High-level, editable Business Model Canvas for Atrys that quickly highlights how the company alleviates healthcare and biotech operational pain points—streamlining diagnostics, data services, and patient pathways. Perfect for teams and boards to condense strategy, speed decision-making, and compare business pivots side-by-side.
Activities
Advanced diagnostics operations
Run integrated imaging, pathology and genomics labs under standardized ISO 15189 protocols, with centralized sample logistics and QA to target 24–72 hour diagnostic turnarounds. Maintain external proficiency testing (EQA) and national accreditation programs to ensure traceability and regulatory compliance. Continuously expand and update test menus and digital reporting workflows in 2024 to include novel biomarkers and structured genomic reports.
AI model development and validation
Build and validate algorithms for image analysis, triage, and decision support, following EU MDR and post‑market surveillance requirements in force through 2024 to enable clinical deployment.
Curate governed, labeled datasets with traceability and consent controls, aligning with GDPR and clinical audit standards used across Atrys’ Spain and Latin America operations.
Conduct bias, accuracy, and robustness testing with clinical partners, then deploy models into workflows with continuous monitoring and performance logging for regulatory reporting.
Radiation oncology planning and delivery
Provide comprehensive treatment planning, contouring, and dosimetry services to design patient-specific radiotherapy protocols. Operate linear accelerators and implement QA systems where applicable to ensure delivery accuracy and safety. Integrate multimodality imaging and genomics to personalize dose, fractionation, and target selection. Continuously track outcomes and toxicity metrics to refine protocols and improve quality of care.
Telemedicine and remote monitoring
Atrys delivers virtual consultations, second opinions and scheduled follow-ups while integrating CE-marked remote devices and mobile apps to continuously track vitals and adherence; clinical alerts trigger escalation to in-person care when predefined thresholds are crossed. All communications and data handling comply with GDPR for Spain, ensuring encrypted channels and strict access controls to protect patient privacy.
- Virtual consults, second opinions, follow-ups
- CE-marked devices and apps for vitals/adherence
- Escalation on clinical thresholds
- GDPR-compliant encrypted communication
Regulatory, quality, and data governance
Atrys maintains ISO, CAP, CLIA, MDR and GDPR compliance across operations, implements SOPs, routine audits and incident response, manages consent, de‑identification and data lineage, and reports performance and safety to clinicians and investors; GDPR exposure can be fines up to €20 million or 4% of global turnover, covering ~447 million EU citizens.
- Compliance: ISO, CAP, CLIA, MDR, GDPR
- Controls: SOPs, audits, incident response
- Data: consent, de‑identification, lineage
- Reporting: performance & safety to stakeholders
24–72h ISO 15189 labs, CE/MDR AI imaging, GDPR fines up to €20 million
Operate ISO 15189 labs with centralized logistics targeting 24–72h diagnostics, expand test menus and structured genomic reports in 2024, and maintain EQA accreditation. Develop CE/MDR‑aligned AI for image analysis with continuous post‑market surveillance and clinical monitoring. Deliver radiotherapy planning, remote consults and CE devices with GDPR controls; GDPR fines up to €20 million or 4% turnover covering ~447M EU citizens.
| Metric | 2024 target |
|---|---|
| Turnaround | 24–72h |
Full Version Awaits
Business Model Canvas
The Atrys Business Model Canvas you’re previewing is the actual deliverable, not a mockup or sample. Upon purchase you’ll receive the same complete, editable file formatted exactly as shown, ready for presentation and use. No hidden pages or placeholders—what you see here is what you’ll download and own.
Resources
Clinical and scientific talent
Atrys deploys clinical teams of roughly 2,000 professionals in 2024, including oncologists, radiologists, pathologists, geneticists and medical physicists to support imaging and therapy programs. Bioinformaticians and data scientists (≈150) drive multi-omics pipelines and AI models used across the network. Clinical operations ensure consistent delivery across ~50 sites, while medical affairs led >200 evidence and education initiatives in 2024.
Accredited labs and imaging infrastructure
Accredited labs combine high-throughput sequencing with pathology and radiology facilities to support multidisciplinary diagnostics and precision medicine workflows. Facilities include advanced MRI, PET-CT and radiotherapy units integrated into diagnostic and therapeutic pathways. Secure HL7 and DICOM connectivity links Atrys systems with hospital PACS and LIS for seamless data exchange. Redundant infrastructure and failover systems ensure continuous operational availability.
Proprietary algorithms and software platforms
Proprietary AI models interpret imaging and genomic data to support diagnostics and treatment decision-making. Workflow orchestration, telehealth, and automated reporting tools streamline end-to-end care paths. Secure APIs (HL7/FHIR, DICOM) enable EHR integration and interoperability. 24/7 monitoring dashboards track performance, safety, and SLAs in production as of 2024.
Clinical data assets
Clinical data assets comprise de-identified imaging, pathology and genomic datasets linked to longitudinal outcomes and real-world evidence repositories. Consent frameworks enable secondary research use while metadata standards (DICOM, HL7 FHIR, MIABIS) ensure reliable analytics across cohorts.
- de-identified multimodal datasets
- longitudinal RWE repositories
- consent-for-research frameworks
- metadata standards for interoperability
Regulatory licenses and payer contracts
Regulatory licenses such as CE‑IVD and national health authority accreditations enable Atrys to offer reimbursable diagnostics and access public payer pathways; market access teams secure insurer contracts and preferred-provider status to drive uptake. Cross-border telemedicine approvals permit remote services across EU jurisdictions, while frameworks for value‑based contracting support outcome‑linked reimbursement pilots in 2024.
- CE‑IVD and national accreditations
- Insurer agreements and preferred-provider contracts
- EU cross-border telemedicine approvals
- Value‑based contracting frameworks (outcome-linked)
Integrated clinical, imaging and AI network - ~2,000 clinicians, ≈150 data scientists
Atrys key resources in 2024 include ~2,000 clinical professionals, ≈150 bioinformaticians/data scientists, ~50 operational sites and >200 medical‑education initiatives; accredited labs with PET‑CT/MRI and radiotherapy units; proprietary AI, HL7/FHIR and DICOM integrations; and de‑identified multimodal RWE repositories supporting value‑based contracts.
| Resource | 2024 metric |
|---|---|
| Clinical staff | ~2,000 |
| Data scientists | ≈150 |
| Sites | ~50 |
| Evidence initiatives | >200 |
Value Propositions
Integrated precision care
Integrated precision care combines imaging, genomics and oncology planning to create personalized treatment pathways, reducing fragmentation by consolidating services under Atrys (founded 2011, listed as ATRYS). This model improves diagnostic confidence and shortens time-to-therapy through coordinated workflows and centralized data. Measurable outcome gains include higher treatment adherence and improved outcomes in molecularly matched patients.
Faster, accurate diagnostics
AI-augmented workflows cut diagnostic turnaround times by up to 30% and reduce error rates by around 20% in 2024 studies, enabling faster, accurate diagnostics. Standardized AI-driven reports improve clinician decision-making with consistent, evidence-based protocols adopted across sites. These protocols ensure reproducible interpretations and auditability, while patients receive timelier answers and faster care pathways.
Expanded access through telehealth
Expand access to underserved regions — WHO estimates roughly 50% of the global population lacks full access to essential health services — by delivering virtual diagnostics and consults, coordinating remote monitoring to maintain continuity and reduce rehospitalizations (studies report up to ~20% reductions), cutting patient travel and wait times, and scaling expert care digitally without heavy capital build-outs; telehealth market was about $90B in 2023, highlighting scale potential.
Cost-effective value-based solutions
Atrys delivers cost-effective, value-based solutions by optimizing resources through triage and right-first-time testing, supporting bundled payments and outcome-tied pricing to lower readmissions and unnecessary procedures; peer-reviewed studies show up to 25% fewer repeat tests and program pilots report 10–15% cost reductions in value-based contracts in 2024.
- Right-first-time: up to 25% fewer repeat tests
- Bundled payments: 10–15% cost reduction
- Lower readmissions: fewer avoidable hospital stays
- Shared savings: aligned payer-provider splits
Research and innovation partnership
Atrys offers a trials, companion diagnostics and RWE platform that accelerates biomarker discovery and validation, delivering high-quality data endpoints to de-risk approvals and strengthen partners’ clinical evidence and market differentiation; real-world evidence spending grew markedly through 2024 as biopharma invests in faster, data-driven launches.
- Platform: trials + CDx + RWE
- Value: faster biomarker validation
- Outcome: high-quality endpoints
- Benefit: stronger evidence, market differentiation
AI precision care speeds diagnosis 30% and expands telehealth access
Integrated precision care consolidates imaging, genomics and oncology under Atrys (founded 2011, listed ATRYS), improving diagnostic confidence and shortening time-to-therapy. AI-augmented workflows cut diagnostic turnaround up to 30% and reduce errors ~20% (2024). Telehealth ($90B market 2023) expands access, lowers rehospitalizations ~20% and supports trials/CDx/RWE with 10–15% cost reductions in value contracts.
| Metric | Value |
|---|---|
| Founded | 2011 |
| Listed | ATRYS |
| AI turnaround | -30% (2024) |
| Error reduction | ~20% (2024) |
| Repeat tests | -25% |
| Cost reduction | 10–15% |
| Telehealth market | $90B (2023) |
| Rehospitalizations | -~20% |
Customer Relationships
Enterprise clinical partnerships
Enterprise clinical partnerships rely on multi-year hospital and health system contracts (typically 3–7 years), backed by dedicated account teams and SLAs with 24/7 support and sub‑24‑hour critical response targets. Joint governance boards meet quarterly to monitor quality and drive innovation. Integrated IT and workflow support teams aim to cut onboarding time by about 30%.
Co-development with pharma
Co-development with pharma centers on joint programs for companion diagnostics and trials, often running 2–4 parallel programs to align biomarker validation with clinical endpoints. Shared data plans and regulatory strategies consolidate real-world and genomic datasets, supporting submissions under EMA/ FDA frameworks and scaling to six-figure sample cohorts. Collaboration structures are milestone-based, with phased payments tied to validation, regulatory clearance and commercialization triggers and typical milestone pools up to tens of millions of euros. Scientific liaison and medical affairs provide ongoing KOL engagement, protocol support and post-market evidence generation to drive uptake and reimbursement.
Provider enablement and education
Provider enablement and education combines clinical training, CME modules and structured onboarding—Atrys delivers integrated decision‑support tools embedded in EHRs and real‑time feedback loops from clinicians to product teams; 24/7 specialist support for critical cases ensures rapid escalation and continuity of care, helping reduce clinical workflow delays and improve adoption metrics.
Patient engagement and support
Patient engagement and support combine clear, actionable reports with counseling and navigation, teleconsults to explain results, and remote monitoring that sends alerts and medication reminders; all communications are privacy-first and compliant with applicable regulations (GDPR/HIPAA where relevant).
- Clear reports, counseling, navigation
- Teleconsults for results explanation
- Remote monitoring with alerts/reminders
- Privacy-first channels; regulatory compliance
Data-driven account management
Data-driven account management at Atrys uses dashboards tracking turnaround, accuracy and outcomes to guide quarterly business reviews and optimization plans in 2024, with benchmarking against peers to identify gaps and prioritize continuous improvement initiatives.
- Dashboards: turnaround, accuracy, outcomes
- Quarterly reviews + optimization plans
- Peer benchmarking
- Continuous improvement
Enterprise contracts 3–7 yrs, 24/7 SLAs
Enterprise contracts 3–7 years with 24/7 SLAs; 2024 onboarding time cut ~30%. Co‑development runs 2–4 parallel programs, milestone pools up to €30M and cohort scaling >100,000 samples. Provider support: embedded EHR tools, 24/7 specialist escalation; patient-facing teleconsults and remote monitoring. Dashboards track TAT 24–48h, analytic accuracy >98% and NPS 65 in 2024.
| Metric | 2024 |
|---|---|
| Contract length | 3–7 yrs |
| Onboarding reduction | ≈30% |
| Parallel programs | 2–4 |
| Milestone pool | ≤€30M |
| Cohort size | >100,000 |
| TAT | 24–48h |
| Accuracy | >98% |
| NPS | 65 |
Channels
Direct sales to providers
Direct enterprise sales target hospitals, clinics and labs with contracting tied to specific service lines; clinical champions and KOLs accelerate adoption through peer-led validation while onsite and virtual demos prove clinical and operational value.
Digital platforms and APIs
Integration with EHR, PACS and LIS via secure APIs enables bidirectional workflows and real-time image/report exchange, with HL7 FHIR supported by all major EHR vendors as of 2024. Web portals allow online ordering and results delivery, reducing report turnaround by up to 30% in comparable digital implementations. Telehealth apps connect patients and clinicians for consults and remote review, while automated notifications and HL7 FHIR workflows ensure event-driven alerts and structured data exchange.
Payer networks and formularies
In-network listing drives utilization—Atrys leverages payer placement to capture referrals as Medicare Advantage enrollment topped about 30 million in 2024. Prior authorization pathways are streamlined to cut administrative delays and improve starts for complex therapies. Patient cost-transparency tools reduce surprises and boost adherence. Value-based agreements are marketed to employers to align outcomes and lower total cost of care.
Research and conference presence
Presentations at oncology, radiology and genomics congresses (eg, ASCO, ECR, ASHG) provide Atrys with peer-reviewed visibility and reach audiences in the tens of thousands at major 2024 meetings, reinforcing clinical credibility. Publications and conference posters translate trial data into trust, supporting referrals and payer discussions. Sponsorships, hands-on workshops and partner booths drive direct engagement, lead generation and joint visibility with clinical and industry stakeholders.
- Presentations: peer-reviewed talks at ASCO/ECR/ASHG
- Publications: posters and papers to build trust
- Sponsorships: workshops for hands-on exposure
- Partner booths: co-branded visibility and lead capture
Channel partners and distributors
Channel partners and distributors: Atrys leverages 15+ regional operators for imaging and lab logistics, OEM device partners bundling its software into hardware packages, telemedicine marketplaces that expanded reach amid a $80B global telehealth market in 2024, and white‑label options for health systems to integrate under their brand.
- Regional operators
- OEM bundles
- Telemedicine marketplaces
- White‑label for systems
Enterprise integrations + telehealth cut report TAT 30%; MA reach 30M
Direct enterprise sales, EHR/PACS/LIS integrations (HL7 FHIR) and telehealth reduce report TAT up to 30% and drive adoption via KOLs and demos. In‑network placement, prior‑auth automation and patient pricing improve starts; Medicare Advantage reach ~30M (2024). 15+ regional operators, OEM bundles and $80B telehealth market (2024) expand referral and distribution.
| Metric | Value |
|---|---|
| Medicare Advantage | ~30M (2024) |
| Regional partners | 15+ |
| Telehealth market | $80B (2024) |
| Report TAT | −30% (digital implementations) |
Customer Segments
Hospitals and health systems
Hospitals and health systems demand integrated diagnostics, oncology care pathways and AI decision support to improve staging, treatment planning and multidisciplinary workflows; over 6,093 US community hospitals (AHA 2023) represent key buyers. They prioritize quality metrics, throughput and cost containment amid a global oncology market exceeding $200 billion (2023). Interoperability with existing EHRs and PACS is mandatory, and they favor multi-year, multi-site contracts to scale value and reduce TCO.
Specialty clinics and imaging centers
Specialty clinics and imaging centers need high-quality reads, second opinions and overflow coverage to cut backlog; scanner idle rates in 2024 remain as high as 40% in some markets, so improving utilization is critical. AI triage and standardized reporting — shown in 2024 studies to reduce report turnaround by up to 30% — deliver faster, predictable-pricing services.
Biopharma and medtech companies
Biopharma and medtech firms use Atrys for companion diagnostics and biomarker services, trial enrollment support and robust endpoint data capture; Atrys supplies regulatory-grade evidence and submissions support to accelerate approvals, and pursues post-market RWE partnerships — the global companion diagnostics market surpassed $4 billion in 2024, underscoring growing demand.
Payers and employer groups
Payers and employer groups prioritize measurable outcome improvements and cost reductions, favoring value-based and bundled payment models that align incentives with patient results. They demand robust reporting, auditability and data provenance to validate savings and clinical impact. Access and member satisfaction are central, driving interest in Atrys services that reduce care delays and improve patient experience.
- Outcome-driven
- Value-based preference
- Audit-ready reporting
- Access & satisfaction focus
Patients and caregivers
Patients and caregivers demand timely, accurate diagnoses and clear guidance, benefiting from Atrys telemedicine and remote monitoring offerings that improve access and continuity of care. Affordability and strong privacy protections are essential, while coordinated, compassionate support enhances adherence and satisfaction.
- Timely diagnostics
- Telemedicine & remote monitoring
- Affordability & privacy
- Coordinated compassionate care
AI diagnostics cut TAT, lift utilization; unlock $4B companion Dx market
Hospitals/health systems (6,093 US community hospitals, AHA 2023) seek integrated diagnostics, AI and multi-site contracts to cut TAT and cost. Imaging centers need utilization gains (scanner idle up to 40% in 2024) and faster reads. Biopharma demands regulatory-grade biomarker/companion diagnostics (> $4B 2024). Payers/employers favor value-based models tied to outcomes.
| Segment | Key metric | 2023/24 stat |
|---|---|---|
| Hospitals | Buyers | 6,093 US hospitals (AHA 2023) |
| Imaging centers | Utilization | Scanner idle up to 40% (2024) |
| Biopharma | Market | Companion Dx > $4B (2024) |
| Payers | Model | Value-based/bundled payment focus |
Cost Structure
Clinical operations and staffing
Salaries for clinicians (typical Spain/Europe ranges €50,000–90,000), scientists (€35,000–70,000) and support teams (€20,000–35,000) form the bulk of Atrys clinical ops costs; labor often represents ~50%–60% of diagnostics OPEX. 24/7 shift coverage increases staffing needs by ~30%–40%. Annual training/credentialing runs about €1,000–3,000 per FTE; outsourcing peak loads can add 10%–20% incremental cost.
Equipment and facility expenses
Capex/leases for imaging/lab/radiotherapy: MRI 1–3M€, CT 0.5–2M€, linear accelerators 4–6M€; maintenance, calibration and QA typically 7–10% of equipment Capex annually; utilities and facility management often represent 2–5% of revenues; depreciation commonly set at 5–7 years for imaging and 7–10 years for radiotherapy, with scheduled upgrades every 5–10 years.
Technology and cloud infrastructure
Technology costs center on cloud compute/storage and cybersecurity as public cloud spend topped 600 billion USD in 2024 (Gartner), with major providers offering SLAs of 99.9–99.99% for core services. Software development, licensing and ongoing API/data-integration maintenance drive recurring OPEX and third-party licenses. Monitoring and uptime SLAs are critical given the 2024 IBM Cost of a Data Breach average of 4.45 million USD.
Regulatory and quality compliance
Regulatory and quality compliance for Atrys encompasses accreditation fees, recurring audits and extensive documentation workflows, plus legal and data-privacy overhead to meet GDPR and medical device rules; insurance and risk management premiums cover clinical liabilities, while post-market surveillance and pharmacovigilance support sustain product safety and reporting obligations.
- Accreditation fees, audits, documentation
- Legal and GDPR compliance overhead
- Insurance and risk management
- Post-market surveillance and pharmacovigilance
Sales, marketing, and partnerships
Sales, marketing, and partnerships costs center on enterprise sales teams and KOL programs deployed in 2024 to drive hospital and lab contracts, plus conference participation and peer-reviewed publications to support clinical adoption. Ongoing account management and training sustain retention and upsell, while partner revenue shares and distribution fees align incentives with channel partners.
- Enterprise sales teams
- KOL programs
- Conferences & publications
- Account management & training
- Partner revenue shares & distribution fees
Salaries 50-60% OPEX; cloud spend 600B USD
Salaries (clinicians €50–90k; scientists €35–70k; support €20–35k) drive ~50–60% of OPEX; 24/7 shifts add ~30–40% headcount. Equipment Capex: MRI €1–3M, CT €0.5–2M, LINAC €4–6M; maintenance ~7–10% p.a. Cloud and security are material—public cloud spend hit 600B USD in 2024. Compliance, insurance and audits add recurring legal/GDPR and post-market costs.
| Item | 2024 Benchmark |
|---|---|
| Labor (% OPEX) | 50–60% |
| MRI Capex | 1–3M€ |
| Maintenance | 7–10% Capex p.a. |
| Cloud spend | 600B USD (global) |
Revenue Streams
Diagnostic service fees
Per-test pricing spans imaging €50–€800, pathology €30–€400 and genomics €500–€3,000, with bundled panels typically €800–€2,500 offering 20–40% cost savings versus standalone assays. Tiered turnaround options run standard 3–10 days and expedited 24–72 hours, often at a 10–30% premium. Services are billed through payer reimbursement or direct provider/payer contracts.
Oncology planning and treatment services
In 2024 Atrys monetizes oncology planning and treatment via per-service fees (contouring $300–800, dosimetry $500–1,500, per-fraction delivery $200–1,000), episode/bundled payments for typical 20–30 fraction courses, add-on premiums for adaptive planning (+10–25%) and second opinions ($200–500), and outcome-linked incentives with partners tying 5–15% of reimbursement to control, toxicity and survival metrics.
SaaS and platform subscriptions
Atrys monetizes AI decision-support, telehealth and workflow tools through SaaS licenses, offered via per-seat and per-site pricing tiers. Integration and annual maintenance fees accompany implementations, while usage-based compute add-ons charge for heavy imaging and AI workloads. In 2024 the company shifted focus toward scalable hospital and enterprise subscriptions. This drives predictable, recurring revenue streams.
Research and pharma collaborations
In 2024 Atrys monetized research and pharma collaborations via milestone and service revenues (typically €0.5–5M per clinical trial), CDx program fees and data licensing from its analytics platform, jointly funded grants and industry-backed studies, and RWE study design/execution fees often ranging €0.1–1M per study.
- Milestones/service fees: €0.5–5M per trial (2024)
- Data licensing & analytics: recurring platform revenue (2024)
- Joint grants: co-funded studies (EU/industry, 2024)
- RWE fees: €0.1–1M per study (2024)
Value-based and shared-savings contracts
Atrys monetizes through outcome-contingent payments tied to quality and cost metrics, aligning revenue with reduced hospital stays, diagnostic accuracy and care-coordination savings. Contracts include gainsharing with payers and providers plus performance bonuses for turnaround and diagnostic accuracy, and increasingly shift to multi-year risk-based arrangements to capture long-term savings.
- Outcome-contingent payments
- Gainsharing with payers/providers
- Performance bonuses for turnaround & accuracy
- Multi-year risk-based contracts
2024 rev mix: diagnostics, oncology services, SaaS & pharma partnerships with 5-15% upside
In 2024 Atrys revenue blends fee-per-test diagnostics (imaging €50–€800; pathology €30–€400; genomics €500–€3,000; bundled €800–€2,500), oncology services (contouring $300–800; dosimetry $500–1,500; per-fraction $200–1,000; episode bundles for 20–30 fractions), SaaS/subscriptions with integration/compute add-ons, and pharma collaborations (€0.5–5M trials; RWE €0.1–1M). Outcome-contingent payments and gainsharing add 5–15% variable upside.
| Revenue stream | 2024 range | note |
|---|---|---|
| Diagnostics | €30–3,000 | bundles €800–2,500 |
| Oncology services | $200–1,500 | episode bundles |
| SaaS | Per-seat/site + usage | recurring |
| Pharma/RWE | €0.1–5M | milestones & data licensing |